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Background: Primary Immunodeficiencies (PIDs) are a heterogeneous group of genetic
immune disorders. While some PIDs can manifest with more than one phenotype,
signs, and symptoms of various PIDs overlap considerably. Recently, novel defects in
immune-related genes and additional variants in previously reported genes responsible
for PIDs have been successfully identified by Next Generation Sequencing (NGS),
allowing the recognition of a broad spectrum of disorders.
Objective: To evaluate the strength and weakness of targeted NGS sequencing
using custom-made Ion Torrent and Haloplex (Agilent) panels for diagnostics and
research purposes.
Cifaldi et al. Targeted NGS Platforms for PIDs
Methods: Five different panels including known and candidate genes were used to
screen 105 patients with distinct PID features divided in three main PID categories: T
cell defects, Humoral defects and Other PIDs. The Ion Torrent sequencing platform was
used in 73 patients. Among these, 18 selected patients without a molecular diagnosis
and 32 additional patients were analyzed by Haloplex enrichment technology.
Results: The complementary use of the two custom-made targeted sequencing
approaches allowed the identification of causative variants in 28.6% (n = 30) of patients.
Twenty-two out of 73 (34.6%) patients were diagnosed by Ion Torrent. In this group 20
were included in the SCID/CID category. Eight out of 50 (16%) patients were diagnosed
by Haloplex workflow. Ion Torrent methodwas highly successful for those cases with well-
defined phenotypes for immunological and clinical presentation. The Haloplex approach
was able to diagnose 4 SCID/CID patients and 4 additional patients with complex and
extended phenotypes, embracing all three PID categories in which this approach was
more efficient. Both technologies showed good gene coverage.
Conclusions: NGS technology represents a powerful approach in the complex field
of rare disorders but its different application should be weighted. A relatively small NGS
target panel can be successfully applied for a robust diagnostic suspicion, while when the
spectrum of clinical phenotypes overlaps more than one PID an in-depth NGS analysis is
required, including also whole exome/genome sequencing to identify the causative gene.
Keywords: primary immunodeficiencies, Next Generation Sequencing, gene panels, Ion Torrent, Haloplex
INTRODUCTION
Primary immunodeficiencies (PIDs) are a phenotypically
and genetically heterogeneous group of more than 300
monogenic inherited disorders resulting in immune defects
that predispose patients to infections, autoimmune disorders,
lymphoproliferative disease, and malignancies (1–3). PIDs with
a more severe phenotype lead to life-threatening infections and
life-limiting complications that require a prompt and accurate
diagnosis in order to initiate lifesaving therapy (4, 5). Phenotypic
and genotypic heterogeneity of PIDs make genetic diagnosis
often complex and delayed. Indeed, more than one genotype
might cause similar clinical phenotypes, but identical genotypes
will not often produce the same phenotype and finally clinical
penetrance may be different (6–9). The characterization of PID-
associated genes is expected to significantly contribute to define
the molecular events governing immune system development
and will provide new insights into the pathogenesis of PIDs.
Molecular genetic testing is also a useful tool for the diagnosis of
PIDs in atypical cases (6, 10).
Abbreviations: AD, Autosomal Dominant; AR, Autosomal Recessive;
CAF, Common Allele Frequency; CDS, Coding Sequence; CID, Combined
Immunodeficiencies; CVID, Common Variable Immunodeficiency; IGV,
Integrative Genome Viewer; MAF, Minor Allele Frequency; NGS, Next
Generation Sequencing; PCR Polymerase Chain Reaction; PID, Primary
Immunodeficiency; SCID, Severe Combined Immunodeficiency; SNP Single
Nucleotide Polymorphism; UTR, Untranslated Region; VCF, Variant Calling
Format; WES, Whole Exome Sequencing; WGS, Whole Genome Sequencing.
Despite the progress in the genetic characterization of
PIDs, many patients still lack a molecular diagnosis. A better
understanding of the genetic and immune defects of patients is
critical to develop therapeutic strategies aimed at changing the
clinical course of the disease and to guarantee an appropriate
genetic counseling allowing the identification of PID patients
before the onset of the disease (11–13). The application of Next
Generation Sequencing (NGS) to PIDs has been a revolution
and it has accelerated the discovery and identification of novel
disease-causing genes and the genetic diagnosis of patients with
monogenic inborn errors of immunity (7, 8, 14–16). Targeted
gene-panel sequencing (17–21), whole exome sequencing (WES)
(22, 23) or whole genome sequencing (WGS) (24) approaches can
rapidly identify candidate gene variants in an increasing number
of genetically undefined diseases (17, 24) and are widely used
in several laboratories for the diagnosis of PIDs (10). WGS also
offers the opportunity to find causative variants in the structural
regions of a given gene. These tools increase the amount of
data analysis that can identify causative genes in both clinically
defined and atypical diseases. Nonetheless, delay in diagnosis can
be caused by the huge amount of data retrieved from whole
sequencing, increased costs sustained by clinical laboratories
and the requirement of trained personnel to validate variants
(7, 8, 22). An increased depth of the sequencing coverage is
generally obtained using targeted gene panels, in favor of a high
accuracy, amelioration of sensitivity andmanagement of datasets,
reducing the time of analysis, the costs and the interpretation of
results, thus accelerating the diagnosis for the majority of PIDs
(14, 16–18). On the other hand, the usefulness of targeted exome
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sequencing approach for the identification of PID patients has
been demonstrated, with accurate detection of point mutations
and exonic deletions in patients with either known or unknown
genetic diagnosis (7, 8).
In this study, we report the clinical and molecular
characterization of 105 PID patients presenting with either
typical SCID/CID or with overlapping PID phenotypes.
Differently from other studies (20, 21, 25), most patients enrolled
in this work had non-consanguineous parents. Two targeted
sequencing approaches were compared to test the ion torrent
reliability in diagnostics and Haloplex Target Enrichment System
in diagnostics and for research purposes. Three diagnostic
panels including known disease genes had been developed for
the Ion Torrent platform (ThermoFisher). The Haloplex panels
comprised well-defined PID genes (>300) and candidate genes
associated with PIDs due to their expression and function in
critical immune-pathways (1, 3). This work underlines how
targeted NGS panels allow a high-throughput low-cost pipeline
to identify the molecular bases of PIDs and are sensitive and
accurate diagnostic tools for simultaneous mutation screening of
known or putative PID-related genes.
MATERIALS AND METHODS
Patients
We report the clinical and molecular characterization of 105
PID patients mainly referred to three centers (2 in Rome
and 1 in Milan) participating in the Italian network of PIDs
(IPINET) and part of The European Reference Network on
immunodeficiency, autoinflammatory, and autoimmune diseases
(ERN RITA). Nine of these patients have been enrolled in the
pCID study (DRKS00000497). Data were obtained from year
2014 to 2017.
Ion Torrent and/or Haloplex panels were applied for the
analysis of samples and compared. Six patients previously
diagnosed by Sanger sequencing were included in the study
(Table 2A) as internal positive controls. The Ion Torrent panels
were used for the analysis of 73 patients with suspicion of
PID. Among this group, 18 patients, still remaining without
a molecular diagnosis and 32 additional patients, were tested
by Haloplex panels (Target Enrichment System for Illumina
platform). The work was conducted in accordance with the
ethical standards of the institutional research committee and
with the 1964 Helsinki declaration and its later amendments
or comparable ethical standards. Informed consent, approved
by the Ethical Committee of the Children’s Hospital Bambino
Gesù, San Raffaele Hospital (TIGET06, TIGET09) and Policlinico
Tor Vergata, was obtained from either patients or their
parents/legal guardians, if minors. Patients and their clinical and
immunological features are reported in Table 1.
Ion Torrent Target System
Panel Design
The construction of targeted panels design required the study
of several reported clinical phenotypes of known PID genes
described in the IUIS (International Union of Immunological
Societies) in the years 2014–2015. Our three custom Ion
Torrent panels were designed with Ampliseq Designer software
using GRCh37 (panel 1 and 2) and GRCh38 (panel 3) as
references. Primers were divided into two pools. The first custom
panel (panel 1) contains 17 known genes related to SCID-
CID phenotypes (85.85 kb). The second custom panel (panel 2)
includes 24 genes for less frequent CID phenotypes (101.9 kb)
and the third panel (panel 3) includes 62 genes for CVID
(240.01 kb) (Supplementary Tables S1–S3). The final design was
expected to cover 95.43% of the first panel, 94.13% of the second
panel and 97.2% of the third genes panel. For each gene included
in the panels a 10 bp of exon padding was included to cover
the flanking regions of exon’s coding sequences (CDS) including
(panel 1 and 2) or not (panel 3) the untranslated regions (UTRs).
Ion Torrent Gene Target Library Preparation and
NGS Sequencing
DNA was extracted by QIAamp DNA Blood Mini Kit
(Qiagen). Five nanograms of gDNA were used for library
preparation. DNA was amplified with 17 amplification cycles
using gene panel Primer Pools and AmpliSeq HiFi mix (Thermo
Fisher). PCR pools for each sample were combined and
subjected to primer digestion with FuPa reagent (Thermo
Fisher). Libraries were indexed using the Ion Xpress Barcode
Adapter Kit. After purification, the amplified libraries were
quantified with Qubit R© 2.0 Fluorometer. All samples were
diluted at a final concentration of 100 pM, then amplicon
libraries were pooled for emulsion PCR (ePCR) on an Ion
OneTouch System 2TM using the Ion PGM Template OT2
200 kit or Ion Chef according to manufacturer’s instructions.
Quality control of all libraries was performed on Qubit R©
2.0 Fluorometer. Ampliseq Design Samples were subjected to
the standard ion PGM 200 Sequencing v2 protocol using
Ion 316 v2 chips or Ion S5 using Ion 520 v2 chips
(Life Technologies).
Ion Torrent Bioinformatics Analysis, Variants Filtering,
and Assessment of Pathogenicity
Mapping and variants calling were performed using the Ion
Torrent suite software v3.6. Sequencing reads were aligned on
GRCh37 (panel 1 and 2) and GRCh38 (panel 3) reference
genome using the program distributed within the Torrent
mapping Alignment Program (TMAP)map4 algorithm (Thermo
Fisher; https://github.com/Ion Torrent/TS). The alignment step
is limited only to the regions of target genes. BAM files
with aligned reads were processed for variant calling by
Torrent Suite Variant Caller TVC program and variants
in Variant Calling Format (VCF) file were annotated with
ANNOVAR. Called variants with minimum coverage of 30X,
standard Mapping Quality and Base Phred Quality were
examined on Integrative Genome Viewer (IGV) and BIOMART.
Filtering procedures selected variants with a minor allele
frequency (MAF) <2% annotated using the following public
databases: 1000 Genomes Project (2500 samples; http://www.
1000genomes.org/), the Exome Variant Server (ESP) (6500 WES
samples; http://evs.gs.washington.edu/EVS/) and the Exome
Aggregation Consortium (ExAC) (60,706 samples; http://exac.
broadinstitute.org/). Nonsense, frame-shift, start lost, stop lost,
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TABLE 2A | Genetic mutations in 6 positive control PID patients.
ID Disease Gene RefSeq Mutation dbSNP and
references
Zygosity Method OMIM
PID I OS RAG1 NM_000448 a) c.1682G>A;
p.R561H
b) c.1871G>A;
p.R624H
rs104894284;
rs199474680
Compound
Heterozygous
Ion Torrent OMIM
*179615
PID II SCID IL2RG NM_000206 a) c.452T>C;
p.L151P
rs137852511 Hemizygous Ion Torrent OMIM
*308380
PID III SCID JAK3 NM_000215 a) c.1208G>A;
p.R403H
Scarselli et al.
(35)
Homozygous Ion Torrent OMIM
*600173
PID IV SCID LIG4 NM_001352601 a) c.833G>A,
p.R278H
b)
c.1271_1275delAAAGA;
p.K424RfsTer20
Cifaldi et al.
(36)
Compound
Heterozygous
Ion Torrent OMIM
*601837
PID V leaky
SCID
RAG1 NM_000448 a) c.2521C>T;
p.R841W
rs104894287 Homozygous Ion Torrent OMIM
*179615
PID VI leaky
SCID
RAG1 NM_000448 a) c.256_257del;
p.K86VfsTer33
rs772962160 Homozygous Ion Torrent OMIM
*179615
In bold novel mutations.
and canonical splice site variants were considered potentially
pathogenic (6). In silico prediction of functional consequences
of novel SNV was performed using Mutation taster, LTR,
Polyphen2, SIFT, and CADD score >15 (26–30) and literature
available data. Supplementary Figure 1A summarizes all steps of
the process.
Haloplex Target System
Panel Design
We designed two panels including up to 300 known PID
genes (3) chosen from a Custom Gene Target Panel from
Agilent SureDesign online tool (http://web16.kazusa.or.jp/rapid_
original/) and about 300 candidate additional genes taken from
the RAPID web site (http://rapid.rcai.riken.jp) from the RIKEN
Center for Integrative Medical Science, from the literature
and the ESID Online Registry. The candidate genes category
includes genes that might be found in clinically relevant PID
pathways and can share similar biological function of known
PID genes. The first panel of 623 target genes comprised 7,245
regions with 66,600 amplicons, while the second panel of 601
target genes, included 6,984 regions and 73,061 amplicons. The
designed probes capture 25 flanking bases in the coding exons
regions (Supplementary Tables 4A,B). The final probe design
was expected to cover>97% of target regions. Practical coverage
is indicated.
Haloplex Gene Target Library Preparation and NGS
Sequencing
Genomic DNA was extracted by QIAamp DNA Blood Mini
Kit (Qiagen) and quantified by Qubit dsDNA BR Assay Kit
(Thermofisher). DNA integrity was check by agarose gel (1%
of agarose in TAE 1x). Genomic DNA was enriched with
Haloplex Target Enrichment System kit (Agilent Technologies
Inc., 2013, Waghäusel-Wiesental, Germany). Libraries were
prepared according to the manufacturer’s instructions. Briefly,
225 ng of genomic DNA was enzymatically digested; fragments
were hybridized with conjugated biotin probes for 16 h at 54◦C.
Circularized target DNA-Haloplex probe hybrids were captured
with streptavidin-coated magnetic beads. DNA ligase was added
to the capture reaction to close nicks in the circularized probe-
target DNA hybrids. All DNA samples were individually indexed
during the hybridization step and library PCR amplification was
performed on the Mastercycler Nexus Thermal Cyclers (Life
Sciences Biotechnology, Hamburg, Germany). Amplicons were
purified with AMPure XP beads (Beckman Coulter, Inc., Krefeld,
Germany). Sequencing was performed with a MiSeq Reagent Kit
v3 (600 Cycles) with 7 pM of sample libraries loaded on the
Illumina MiSeq (San Diego, CA, USA). Quality controls after
fragmentation and final concentration of prepared libraries, were
assessed by Bioanalyzer (Agilent Technologies Inc., Eindhoven,
the Netherlands).
Haloplex Bioinformatics Analysis, Variants Filtering,
and Assessment of Pathogenicity
FastQ files were aligned to the human reference genome (UCSC
hg19, GRCh37) by Burrows–Wheeler Aligner (31). Picard
HsMetrics was applied to analyze the target-capture sequencing
experiments (http://picard.sourceforge.net/) and internal scripts
were used to calculate mean gene coverage. Variant calling was
performed by Freebayes (32). Raw variants were filtered by the
following parameters: QUAL> 1, (QUAL/AO)> 10, SAF> 0,
SAR> 0, RPR> 1, RPL > 1. Variants with an allele depth below
20 reads were excluded from the analysis. Selected variants were
annotated for dbSNP-146, ClinVar, dbNSFP v2.9 databases and
SnpEff (33) and were filtered for Common Allele Frequencies
(CAF) <5% and variant effect on exons (missense, frameshift,
splice acceptor/donor, start lost, stop lost, stop gained, 3′UTR,
5′UTR). Variants found in the either 5′ or 3′ UTR were excluded
from the subsequent analyses. In silico analysis for variants’
pathogenicity was determined according to 5 prediction tools:
Mutation taster, LTR, Polyphen2, SIFT, and CADD score >15
(26–30). In case of trios, variants were subdivided according to
model of inheritance (Autosomal Recessive/Dominant, X-linked,
De novo). The complete bioinformatics analysis is reported in
Supplementary Figure 1B.
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Statistical Analysis
Data were analyzed with Graph-Pad Prism, version 6.2 (Graph
Pad Software, la Jolla, CA).
RESULTS
Characterization of PID Patients
In this study, we report the clinical and molecular
characterization of 105 PID patients presenting with either
typical or overlapping PID phenotypes. Patients were clustered
according to initial clinical presentation in 3 main categories
(Figure 1A): T-cell defects (including Omenn syndrome, SCID,
CID, syndromic T-cell defect, unclassified T-cell deficiency, hyper
IgM syndrome); Humoral defects (agammaglobulinemia, CVID,
unclassified antibody deficiency, dysgammaglobulinemia);
Other PIDs (immune dysregulation, innate immunity defects
including congenital defects of phagocytes, syndromic defects
with immune-deficiency signs/symptoms, ALPS-ALPS-like,
autoinflammatory syndrome, and a miscellaneous that includes
non-typical PID patients with a broad range of clinical
phenotypes). The clinical, immunological, and molecular
features are reported in Table 1. The percentage of patients in
each subgroup is shown in Figures 1B–D. Among the T-cell
defects (n = 50; 47,7%), the majority of patients presented with
SCID (48%), followed by CID (32%) (Figure 1B). The Humoral
Defects group (n = 28; 26,6%) was mainly represented by CVID
(75%), while the Other PIDs group (n = 27; 25,7%) included a
wide spectrum of rare defects and uncommon phenotypes.
Seventy-three PID patients were analyzed by Ion Torrent
sequencing system using three different panels including
SCID/CID and CVID known genes. Two Haloplex panels
including more than 600 known and candidate PID genes
FIGURE 1 | Clinical diagnosis of patients at admission. (A) Percentage of patients for three main categories. Percentage of each clinical diagnosis in patients
belonging to (B) T cell defects, (C) Humoral defects and (D) Other PIDs categories. For each category the total number of patients is indicated.
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were applied to 32 additional patients. Additionally, 18 patients
previously analyzed by Ion Torrent but still without a clear
molecular diagnosis, were analyzed by Haloplex system. A flow
chart showing the route map for sequencing of index patients is
shown in Figure 2.
Target Enrichment Performance and Gene
Coverage
The mean target coverage resulted of 529 ± 169X (panel 1),
361 ± 97X (panel 2) and 417 ± 117X (panel 3) for Ion Torrent
and 229± 25X for Haloplex panels (Supplementary Figure 2A).
The mean target coverage for Ion Torrent panels was optimal
as compared to recently published works in which a coverage
of 335X was obtained (34). Indeed, the Ion Torrent expected
coverage of the coding regions was 95.43% for panel 1
(SCID-CID), 94.13% for panel 2 (rare CID) and 97.2%
for the panel 3 (Supplementary Tables 1–3). The practical
coverage obtained from Ion Torrent panels is shown in
Supplementary Figures 2B–D.
Primer design for Haloplex aimed at covering more than 97%
of the coding regions for all genes. The observed coverage of
the targeted regions after running the two panels is represented
in Supplementary Tables 4A,B. The majority of shared genes
included in all panels and analyzed by both technologies were
well-covered (Supplementary Figures 3A–C).
Performance Evaluation
The use of large panels for NGS retrieved a big number of data
as compared to small panels. Putative variants detected by Ion
Torrent have been examined and validated obtaining an average
of false positive variants <0.6%. Such value decreases reducing
the number of genes included in the panel. Haloplex produces
larger amount of variants, but only the ones significantly
indicative among those related to the patient’s phenotype have
been investigated; hence, we could not properly evaluate data
accuracy. In the 18 patients resequenced by Haloplex, no
variants in genes included in the Ion Torrent panels were
found supporting the accuracy of these methods. Furthermore,
FIGURE 2 | Flowchart indicating the strategy of the study. (1) Indicates the only patient in Humoral defect group who has been analyzed by Ion Torrent panel 1.
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FIGURE 3 | Comparison between different number of genetic diagnoses obtained by Ion Torrent and Haloplex. (A) Histogram showing the number of overall
diagnosed (red), under investigation (orange) or undiagnosed (gray) patients. (B) Histogram showing the Ion Torrent diagnoses. (C) Histograms showing Haloplex
diagnoses. (D) Diagnostic findings by Haloplex in negative Ion Torrent patients. The percentages refer only to diagnosed patients.
6 available samples previously diagnosed by Sanger sequencing
with 8 known different mutations in RAG1, IL2RG, JAK3, and
LIG4 genes, were included in the study and detected by Ion
Torrent panel 1 (Table 2A).
One false negative diagnosis has been recently recognized.
Indeed, the Torrent Suite Variant Caller TVC program was
unable to identify the c.C664T: p.R222C mutation in exon
5 of IL2RG gene in patient PID16 but this was detectable
on IGV.
Molecular Diagnoses
In our cohort, 28.6% (30/105) of molecular diagnosis was
obtained (Figure 3A). Sanger sequencing for all mutations and
parents’ carrier status were performed. Functional studies were
conducted for most novel variants and results are reported
in Table 2B.
A rapid molecular diagnosis was established in 30.1% (22/73)
of PID patients who were investigated by Ion Torrent. Diagnoses
were achieved in RAG1, RAG2, IL2RG, JAK3, ADA, CD3D,
IL7R, CD40L, and XIAP genes (see Table 2B). As expected, the
identification of a molecular defect resulted more frequent in
patients with a clear clinical and immunological phenotype as
shown in those included in the group of T cell defects (20/42;
47.6%) (Figure 3B). Interestingly, the percentage of diagnosis in
the group of SCID/CID patients was 60.6% (20/33).
The percentage of molecular diagnosis for the 50 patients
studied through the Haloplex panels was of 16% (8/50) as shown
in Figure 3A. The first 6 diagnoses were obtained in a cohort of
32 patients. Three SCID/CID patients with mutations in RAG1,
IL7R and ARPC1B genes [(40, 45–47) and Volpi et al., under
revision] were diagnosed in 8 T cell defects (37,5%). Moreover,
JAGN1 (48), CECR1 (43) and NRAS genes, associated to complex
phenotypes, were identified in 12 of the Other PIDs group
(25%) (Figure 3C).
Two additional patients were diagnosed analyzing the 18
patients, previously negative by Ion Torrent, presenting with
a less defined immunological phenotype (Figure 3D). For one
patient (PID12), the Ion Torrent panel 1 was able to detect
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only a missense mutation in the ADA gene. Haloplex identified
the second intronic mutation located in the fifth nucleotide
upstream exon 5, not included in the Ion Torrent design,
of the gene. In the second Ion Torrent negative patient
(PID82) presenting an atypical HyperIgE syndrome, Haloplex
detected two rare homozygous mutations inMYD88 and CARD9
genes, which were not included in the Ion Torrent panels
(1 and 2). The pathogenic role of each single gene mutation
is still under investigation but this molecular information is
important to optimize the clinical management of the patient
including the evaluation of HSCT as definitive treatment
(44).
In summary, 4 SCID/CID patients out of a total of 16 T
cell defects, were identified by Haloplex, demonstrating once
more a higher percentage of diagnosis in this PID group
(Table 2B). However, although the possibility to identify a
causative gene mutation correlates with a precise clinical
clusterization, the identification of patients, with complex and
extended phenotypes, needs larger NGS panels.
Disease-Associated Variants
Comparing the results obtained by the two methods, 44 (32 Ion
Torrent and 12 Haloplex) disease-associated variants have been
identified in 30 patients, of whom 18 were novel (Table 2B). The
majority of variants detected by Ion Torrent were missense (n
= 23; 74.2%) as summarized in Figure 4A. We were also able to
detect 4 small deletions and 5 splice site variants. The Haloplex
panels detected 5 missense, 2 deletions, 4 splice site and 1 stop
codon variants (Figure 4B). Among the 30 diagnosed patients,
we found 13 compound heterozygous patients with mutations
in RAG1, JAK3, ADA, IL7R, and CECR1 genes, 9 homozygous
variants including ADA, RAG1, RAG2, CD3D, JAK3, ARPC1B,
MYD88/CARD9, and JAGN1, 7 hemizygous variants in IL2RG,
CD40LG, and XIAP, and only 1 heterozygous somatic variant
in NRAS (Figure 4C). Therefore, most patients enrolled in this
study were offspring of non-consanguineous marriages. The
most frequent mutated gene in our cohort is RAG1 followed by
IL2RG (Figure 4D).
Putative Neutral Variants vs. Variants of
Uncertain Significance (VUS)
Fifteen CVID patients were initially analyzed by Ion Torrent
panels 1-2, but no causative variants were found. We therefore
designed a specific CVID panel and found 4 putative causative
variants suggestive of AD disease that was confirmed by Sanger
sequencing. Indeed, we found a heterozygous damaging variant
in theCTLA4 gene and a predicted damaging variant in the PTEN
gene in an adult patient followed since childhood (PID56). The
patient inherited one mutation from the father and one from
the mother but the real role of these variants and their possible
combined effect is still under investigation. In addition, two other
VUS in TCF3 and PLCG2 genes were found in two patients
(PID75 and PID54), in which no other evidences are available
(see Table 1).
A rare variant in CD40L gene (p.R200S) found in patient
PID50 was excluded from the analysis, although an altered
CD40L expression was detected. This variant was predicted
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FIGURE 4 | Type and zygosity of mutations and mutated genes distribution. Types and percentage of mutations found in diagnosed PID patients for Ion Torrent (A)
and Haloplex (B). (C) Overall observed zygosity for diagnosed PID patients. (D) Total number of detected mutated genes.
benign in multiple databases. Furthermore, a homozygous rare
variant in CECR1 gene (p.Q233R) was found in patient PID13.
However, the two proband’s healthy brothers were found to
be homozygous for this variant thus it was not considered
pathogenic, nevertheless, additional functional studies will be
performed to exclude genetic predisposition (e.g., ADA2 activity,
protein expression).
Three novel variants of uncertain significance (VUS)
identified by Haloplex in patients with classical and
complex phenotypes are still “under investigation.” We
are currently validating a novel damaging variant in
the TCF3 gene in two twin patients (PID57-58) and
their mother affected by CVID (49). EMSA assay is
ongoing to assess the capacity of TCF3 protein to bind
DNA target sequences. In these twin patients we also
previously found by Sanger sequencing a mutation in
TNFRSF13B gene already described to be associated to
CVID (50).
A causative variant in the BMP4 gene (51) with a severe
myopia, ectodermal dysplasia, and cytopenia was found in a
patient (PID95) in whom the altered immunological phenotype
remains poorly explained by this mutation. Moreover, NFκB1
variant in a CID patient (PID38) was found but its significance
is still under investigation.
Finally, heterozygous variants in TNFRSF13B (PID70, PID87)
and NOD2 (PID77), genes were found by Haloplex in three
patients. Generally, variants in susceptibility genes involved in
the disease pathogenesis should be considered for potential
future phenotypic implications particularly in adult patients
where multiple factors may contribute to the onset of
the disease.
DISCUSSION
The application of multigene NGS panels has extended
our knowledge of PIDs and is currently recognized as a
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comprehensive diagnostic method in the field of rare disorders
consenting the diagnosis in the 15–70% of all cases depending
on the PID clinical and phenotypic clusterization (25, 52). In
the present work we show that the complementary, integrated
use of two custom-made targeted sequencing approaches, Ion
Torrent or Haloplex, allowed to clearly identify causative variants
in 28.6% (n= 30) of the patients in all groups of PIDs, confirming
the value of NGS assays to obtain a genetic diagnosis for
PIDs (17–23).
The Ion Torrent approach resulted highly successful for SCID
patients, a group generally more defined for its immunological
and clinical presentation (53). Indeed, with this approach we
identified 20/33 SCID/CID patients (60,6%). The Haloplex
workflow was able to identify causative variants in 8/50 patients
(16%) of whom 4 were found in the group of SCID/CID
patients and 4 fall in that of complex and extended phenotypes.
Interestingly, a molecular diagnosis was achieved in 2/18 (11%)
patients presenting with typical and atypical clinical phenotypes
resulted negative after Ion Torrent analysis and included in the
Haloplex approach.
By NGS it is possible to identify unexpected mutations in
apparently not corresponding PID cases, as recently reported
by our group for a patient with agammaglobulinemia due to
RAG1 deficiency (41). This result strengthen the notion of a large
phenotypic variety associated with RAG deficiency, suggesting
that it should be considered also in patients presenting with an
isolated marked B-cell defect (54–57) and as already reported
that RAG mutations are more frequent than expected. Notably,
RAG1 is the most frequent PID cause in our cohort. This case
represents a paradigmatic model of how new questions arise
on the management and follow-up for patients in which a
milder phenotype could be associated to alternative treatments
to transplantation (41, 57, 58).
CVID is a typical example of a disease with a broad
phenotype due to different gene alterations (59–61). Notably,
in 4 CVID patients with mutations in TNFRSF13B and AIRE
previously detected by Sanger sequencing (see Table 1) we
extendedNGS analysis to looking for novel disease causing genes.
Therefore, frequent variants comparable to polymorphisms
should be considered with caution since the pathogenic meaning
is still unclear. Additional functional studies in these cases
are required. Four additional diagnoses are summarized in
Supplementary Table 5 (62). These were obtained after the
completion of the present study by other targeted NGS panels
and Sanger sequencing, indicating that the combination of in-
depth clinical knowledge and appropriate sequencing techniques
can lead to new diagnoses.
Although the prioritization methods applied in this
study follows all common assumptions for a correct data
analysis, the identification of novel variants currently under
investigation represents a challenge and their validation
needs the essential support of further in-depth experimental
studies (6–8, 63). The integration of clinical, immunological,
biochemical and molecular data might favor a revised PIDs
classification of patients with similar phenotype due to a
different genetic cause, or patients with different phenotypes
but with the same genetic cause. In our experience, the
use of selected NGS panels is useful and easy to handle
for rapid diagnosis in clinically and immunologically well-
characterized phenotypes. As compared to WES, targeted small
NGS panels provide an important alternative for clinicians
for direct sequencing of relevant genes, guaranteeing a high
coverage and sequencing depth (64). On the contrary, their
application in patients with atypical phenotypes could result
in an incomplete and delayed diagnosis. Extended gene
panels or WES should be directly used in these cases for
research purposes, to allow the diagnosis of unexpected
genotype-phenotype association.
As reported by several groups (7, 8, 22–24), the application
of targeted WES for each suspicion of PID by exploring
gene-by-gene also for limited numbers of striking genes still
remain time and resource consuming in the absence of
synergy between clinical and bioinformatics supports. This is
yet unfeasible for extended diagnostic purposes. Indeed, the
huge amount of retrieved data and the risk of incidental
findings in other non-PID genes involved in different monogenic
or multifactorial pathologies may be confounding and do
not corresponding to the first suspicion. Additionally, the
confidence of the results decreases with the number of
targeted genes and may preclude any variant detection in
self-evident known genes (65). Many previously undetected
variants do not have a well-defined role in our genome
(1.5 × 106 million variants in each genome and lesser in
exome). In this scenario, ethical and legal issues related to
the disclosure of genetic information generated by NGS need
to be considered and guidelines should be developed to help
the different specialists to translate the genetic results into the
clinics (64).
The achievement of NGS application will require further
integration of knowledge based on clinical, immunological
and molecular data and the collaboration among different
experts in these fields. A better clinical, immunological and
genetic characterization of new PIDs will significantly contribute
to the identification of diagnostic and prognostic markers
and early individual therapeutic strategies with significant
patients’ benefit.
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